ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases
ProQR Therapeutics N.V. - Ordinary Shares (PRQR)
Last proqr therapeutics n.v. - ordinary shares earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
proqr.com
Company Research
Source: GlobeNewswire
LEIDEN, Netherlands and CAMBRIDGE, Mass, Feb. 06, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, announced today its participation in the Foundation Fighting Blindness My Retina Tracker Program, a collaborative, open access program run by Blueprint Genetics and InformedDNA providing no-cost genetic testing and genetic counseling for individuals with a clinical diagnosis of an inherited retinal disease (IRD) such as Leber’s congenital amaurosis (LCA) and Usher syndrome, amongst others. Many people diagnosed with an IRD have not received genetic testing. In absence of knowing the genetic mutation, eligibility for clinical trials or available treatments is more difficult to determine. Genetic testing in the My Retina Tracker Program is performed by Blueprint Genetics and tests a broad panel of known mutations causing IRDs, including mutations c
Show less
Read more
Impact Snapshot
Event Time:
PRQR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRQR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRQR alerts
High impacting ProQR Therapeutics N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PRQR
News
- Is There An Opportunity With ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 37% Undervaluation? [Yahoo! Finance]Yahoo! Finance
- ProQR Therapeutics (NASDAQ: PRQR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $8.00 price target on the stock.MarketBeat
- ProQR Therapeutics (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- ProQR Therapeutics (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.MarketBeat
- ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration [Yahoo! Finance]Yahoo! Finance
PRQR
Earnings
- 11/7/24 - Beat
PRQR
Sec Filings
- 12/12/24 - Form 6-K/A
- 12/11/24 - Form 6-K
- 12/11/24 - Form 6-K
- PRQR's page on the SEC website